{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":90,"width":600,"title":"Prasugrel Benefits Patients With Diabetes and Multivessel Disease Post-PCI: TUXEDO-2\u202fTrial","description":" The findings from the TUXEDO\u20112 trial&amp;nbsp;provide&amp;nbsp;important clinical insights for managing high\u2011risk patients with diabetes and multivessel coronary disease undergoing stenting. By directly comparing ticagrelor and prasugrel within a dual antiplatelet therapy regimen, the trial helps clarify whether one agent offers superior protection in this complex population. These results may influence clinical decision\u2011making, particularly if meaningful differences in outcomes are&amp;nbsp;demonstrated.&amp;nbsp;   In this interview,&amp;nbsp;Sidney C. Smith Jr., MD, MACC and\u202fSripal&amp;nbsp;Bangalore, MD, MHA discuss\u202fthe\u202fTUXEDO-2 Trial.&amp;nbsp;   \u202f&amp;nbsp;  ","author_name":"ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research","author_url":"http:\/\/accelaccorg.libsyn.com\/website","html":"<iframe title=\"Libsyn Player\" style=\"border: none\" src=\"\/\/html5-player.libsyn.com\/embed\/episode\/id\/40370940\/height\/90\/theme\/custom\/thumbnail\/yes\/direction\/forward\/render-playlist\/no\/custom-color\/88AA3C\/\" height=\"90\" width=\"600\" scrolling=\"no\"  allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen><\/iframe>","thumbnail_url":"https:\/\/assets.libsyn.com\/secure\/item\/40370940"}